Drug intelligence / Profile preview

bifidobacteria + lactobacillus + maltodextrin

Development stage: Unknown
Lead developer: Southern Medical University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This combination consists of two major genera of lactic acid-producing bacteria, *Bifidobacterium* and *Lactobacillus*, paired with maltodextrin, which typically functions as a carrier, stabilizer, or prebiotic. These probiotics are widely used to maintain or restore the natural balance of the intestinal microbiota. *Lactobacillus* species primarily colonize the small intestine, while *Bifidobacterium* species are more prevalent in the large intestine. Together, they work by competing with pathogenic microorganisms for adhesion sites and nutrients, producing antimicrobial substances like lactic acid and bacteriocins, and enhancing the intestinal barrier function. Maltodextrin is often included to stabilize the live cultures and may provide a fermentable substrate for the bacteria. This combination is commonly indicated for the management of digestive health, including diarrhea, irritable bowel syndrome (IBS), and antibiotic-associated dysbiosis.

Other names: bifidobacteria + lactobacillus + maltodextrinprobiotic combination with maltodextrin

Beyond the preview

Go deeper on bifidobacteria + lactobacillus + maltodextrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacteria + lactobacillus + maltodextrin.

Explore the full profile